BMS Archive

Plant · Scientific monograph

Melissa officinalis

Lemon Balm

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Anxiolytic Research, Cognitive Research, Sleep Research, Antiviral Research

Research overview

Historical use

Melissa officinalis (lemon balm) has been used in European herbal medicine since at least the 10th century, when Arab physicians including Avicenna praised it for strengthening the heart, dispelling melancholy, and improving memory. The name 'Melissa' derives from the Greek for honeybee — the flowers are a rich source of nectar. European monastic medicine, particularly the Carmelite tradition, produced 'Carmelite water' from lemon balm, angelica root, and lemon peel as a popular anxiolytic tonic distributed from the 17th century onwards. Paracelsus considered it one of the elixirs of life. Traditional uses span anxiety, insomnia, headache, palpitations, digestive upset, and as a topical antiviral for herpes labialis. Its pleasant lemon-mint aroma made it one of the most widely cultivated medicinal herbs in European kitchen gardens.

Modern research context

A 2021 systematic review found evidence supporting significant reductions in anxiety and mood disturbance in human trials, with reported effects across populations including healthy volunteers, menopausal women, and patients with chronic illness [1]; note that heterogeneity across included trials and variable study quality limit the strength of conclusions. A 2021 RCT demonstrated significant improvements in cognitive function — specifically memory recall and attention — in older adults following 8 weeks of supplementation with standardized extract [2]. For herpes labialis (oral herpes), a proprietary topical lemon balm cream (LomaHerpan) has Level B RCT evidence for reducing healing time and recurrence frequency of cold sores — rosmarinic acid and caffeic acid derivatives inhibit HSV-1 attachment. [Primary RCT citations — Koytchev et al. 1999 and Wolbling & Leonhardt 1994 — must be verified and added to cited_references; PMIDs required.] Sleep improvement in combination with valerian has Level B RCT evidence [valerian/lemon balm combination RCT citation required — PMID needed]; monotherapy sleep data is weaker (Level C). Anti-anxiety effects appear primarily mediated through GABA transaminase inhibition, offering a pharmacological basis for the traditional anxiolytic use.

Adverse effects

Melissa officinalis has one of the most favourable tolerability profiles among anxiolytic herbs. The most frequently reported adverse effects in clinical trials are mild drowsiness and sedation, particularly at higher doses — consistent with the GABAergic mechanism. GI discomfort (nausea, abdominal pain) is reported occasionally. There is a theoretical concern that rosmarinic acid may inhibit thyroid peroxidase activity in vitro, potentially affecting thyroid hormone synthesis at very high doses; the clinical significance at typical supplemental doses has not been established in human studies. Paradoxical anxiety or agitation has been reported very rarely.

Contraindications

Hypothyroidism or concurrent thyroid medication use — theoretical inhibition of thyroid hormone synthesis; avoid high doses and monitor thyroid function. Glaucoma — theoretical intraocular pressure effects from GABA-related mechanisms (unconfirmed in human data). Pre-surgery: additive sedation with anaesthetics; discontinue 1 week prior. Concurrent sedatives, benzodiazepines, barbiturates, or opioids — additive CNS depression.

Clinical and phytochemical data

Used part

Leaves and aerial parts (fresh or dried; aqueous infusion or standardized hydroethanolic extract). Essential oil used in aromatherapy (distinct from oral preparations).

Primary active compounds

  • Rosmarinic acid (caffeic acid derivative, ~1–7% dry weight) — primary anxiolytic; GABA-T inhibitor; antiviral

  • Caffeic acid and chlorogenic acid (hydroxycinnamic acids) — antioxidant, antiviral

  • Luteolin, apigenin, luteolin-7-glucoside (flavonoids) — anti-inflammatory, anxiolytic

  • Ursolic acid and oleanolic acid (triterpenoids) — anti-inflammatory

  • Volatile oils: citral (geranial + neral), citronellal, linalool, β-caryophyllene — aromatic, mild anxiolytic in aromatherapy

  • Hydroxy-cinnamic acid esters and salvianolic acids

Mechanism of action

The primary anxiolytic mechanism involves rosmarinic acid inhibiting GABA transaminase (GABA-T) — the enzyme responsible for GABA catabolism. By slowing GABA breakdown, rosmarinic acid elevates synaptic GABA concentrations, producing anxiolytic and mild sedative effects without direct benzodiazepine receptor binding [1]. Luteolin and apigenin additionally act as positive allosteric modulators at GABA-A receptors, enhancing chloride channel conductance. Cognitive benefits are attributed to inhibition of acetylcholinesterase (AChE) by rosmarinic acid and related phenolics, increasing acetylcholine availability in cholinergic synapses [2]. Antiviral activity against herpes simplex virus (HSV-1 and HSV-2) is mediated through rosmarinic acid and caffeic acid derivatives that block viral glycoprotein binding to heparan sulfate receptors on host cells, preventing viral attachment and entry. Anti-inflammatory effects involve inhibition of NF-κB and COX-2 by rosmarinic acid.

Pharmacokinetics

Absorption

Human PK data available for rosmarinic acid. Oral bioavailability of rosmarinic acid from lemon balm extract is moderate (~36%), with Tmax approximately 0.5–1 hour. Absorption is influenced by food matrix and extract formulation. Caffeic acid and its glucosides are also absorbed and undergo intestinal hydrolysis and bacterial conversion.

Distribution

Rosmarinic acid: plasma protein binding approximately 90%. Distributes to liver, kidney, and intestinal mucosa. CNS penetration of rosmarinic acid has been demonstrated in rodent models, consistent with central GABA and cholinergic effects. Volume of distribution in humans not formally reported.

Metabolism

Rosmarinic acid undergoes extensive phase II metabolism: methylation (COMT), glucuronidation, and sulfation in the liver and intestinal wall. Gut microbiota further metabolize polyphenols to phenylpropionic acid derivatives and other ring-fission products that may contribute to systemic effects. The essential oil volatile components are rapidly absorbed transdermally and via inhalation, undergoing hepatic oxidation.

Excretion

Rosmarinic acid metabolites primarily excreted renally as glucuronides and sulfate conjugates. t1/2 of rosmarinic acid approximately 1–3 hours in plasma; metabolites have longer apparent half-life. Complete elimination of phenolic metabolites within 24 hours.

Safety and interactions

Drug interactions

CNS depressants (benzodiazepines, barbiturates, opioids, sedative antihistamines, alcohol): additive sedation through GABAergic mechanism — reduce co-administered sedative dose if combining; avoid alcohol co-use. Thyroid medications (levothyroxine, antithyroid drugs): rosmarinic acid inhibits thyroid peroxidase in vitro; clinical significance uncertain but monitoring thyroid function recommended with concurrent use and high doses. Cholinesterase inhibitors (donepezil, rivastigmine): additive AChE inhibition — potential for additive cognitive benefit but also additive cholinergic adverse effects (GI cramping, bradycardia). Antivirals (aciclovir) — potential additive antiviral effects for herpes labialis; no adverse interaction identified.

Toxicity

Melissa officinalis has a well-established tolerability profile in short-term clinical trials (up to 8–16 weeks) and centuries of food-level use; formal long-term safety data from controlled studies are absent, and absence of reported adverse events should not be interpreted as confirmed safety beyond the studied durations. No significant hepatotoxicity, nephrotoxicity, or cardiotoxicity documented in human trials. Mild sedation at higher doses is the primary dose-limiting effect. No mutagenicity in standard assays. LD50 in animals is high. GRAS (Generally Recognized as Safe) status for food use in the USA. Long-term safety data from controlled trials is limited to 8–16 weeks; traditional use at low doses suggests long-term safety at dietary doses.

Special precautions

Pregnancy

Insufficient clinical safety data for medicinal-dose use during pregnancy. Food-level consumption (teas at dietary amounts) is generally considered low-risk. Medicinal-dose supplementation not recommended due to absence of controlled pregnancy safety data. Evidence basis: no controlled human data.

Lactation

Insufficient safety data for medicinal doses. Rosmarinic acid and volatile oil constituents may be excreted in breast milk. Traditional use in gentle teas at low dietary doses may be acceptable but medicinal-strength supplementation is not recommended.

Hepatic impairment

No hepatotoxicity documented in clinical literature. Rosmarinic acid undergoes hepatic phase II metabolism. No formal pharmacokinetic studies in hepatic impairment; standard precautions apply for significantly impaired hepatic function.

Renal impairment

Rosmarinic acid metabolites are primarily renally excreted. No formal studies in renal impairment. Use with caution in severe renal impairment.

Sources and references

  1. [1] - Haybar H et al., "Melissa officinalis for anxiety and depression: systematic review", Int J Nurs Stud, 2021, PMID: 33901940
  2. [2] - Ghazizadeh J et al., "Melissa officinalis for cognitive function", Phytother Res, 2021, PMID: 34449930
  3. [3] - Farber T et al., "Lemon balm for occupational therapy and anxiety", Am J Occup Ther, 2020, PMID: 32204779
  4. [4] - Kennedy D et al., "Anxiolytic and sedative effects of preparations of Melissa officinalis", Phytomedicine, 2002 — cited in safety review, PMID: 32025928 [CRITICAL: this PMID range (~32M) corresponds to a ~2020 publication, not the Kennedy 2002 lemon balm paper. The Kennedy DO et al. lemon balm anxiolytic paper is likely near PMID 12062564 or 15272110 — must be corrected via manual PubMed verification before publication]
  5. [5] - Ulbricht C et al., "Lemon balm: a natural product evidence-based overview", Altern Ther Health Med, 2005, PMID: 23472485 [PMID range inconsistent with 2005 date — verify in PubMed]

Additional source links

Continue browsing